Phase 2 COSMOS study results published in The Lancet demonstrate efficacy and safety of Janssen’s once-daily imeprevir
29 July 2014 | By Janssen
... in all oral 12-week combination with sofosbuvir for genotype 1 chronic hepatitis C.
List view / Grid view
29 July 2014 | By Janssen
... in all oral 12-week combination with sofosbuvir for genotype 1 chronic hepatitis C.
16 July 2013 | By Amgen
Phase 2 study reports safety and efficacy results in patients with giant cell tumor of bone...
23 April 2012 | By Novo Nordisk
Two studies show a significant reduction in the rates of nocturnal hypoglycaemia by 25%, compared to insulin glargine...